Nektar Therapeutics disclosed that 71% of patients who achieved an EASI‑75 response during the 16‑week induction phase maintained that level of improvement at week 52, and 83% maintained a vIGA‑AD 0/1 response, indicating sustained disease control in a majority of participants.
The strongest durability was observed with the 24 µg/kg dosing schedule. 71% of patients on the monthly regimen and 83% on the quarterly regimen maintained EASI‑75, while new EASI‑100 responses were seen in 22% of the monthly group and 18% of the quarterly group, underscoring the potential for deepening clearance with less frequent dosing.
These results validate rezpegaldesleukin as a first‑in‑class regulatory T‑cell (Treg) stimulator and support the company’s plan to launch a pivotal Phase 3 trial in the second quarter of 2026, with a Biologics License Application filing targeted for 2029. The data also reinforce the Fast‑Track designation the FDA granted for the atopic dermatitis indication.
The positive durability profile is expected to bolster investor confidence and support Nektar’s announced $300 million public offering of common stock and pre‑funded warrants, announced on the same day. The capital raise will provide the cash needed to fund the upcoming Phase 3 program and to pursue potential partnership discussions.
Following the announcement, Nektar’s shares surged, and analysts upgraded ratings and raised price targets. The market reaction was driven by the durable efficacy data, the validation of the novel Treg mechanism, and the company’s clear regulatory pathway and capital‑raising strategy.
CEO Howard W. Robin said, “These new REZOLVE‑AD study results reinforce the promise of the Treg mechanism to treat atopic dermatitis. The combined data from induction and maintenance now showcase the potential of a Treg biologic to offer compelling efficacy and safety advantages and less frequent maintenance dosing.” Dr. Jonathan Silverberg added, “Rezpegaldesleukin is emerging as one of the most important mechanisms in development for atopic dermatitis.”
Nektar’s financial health remains a consideration. Revenue declined year‑over‑year due to the sale of a manufacturing facility, and the company reports negative operating and net margins. However, a strong balance sheet and sufficient cash reserves extend the runway to Q2 2027, and the proposed public offering is intended to strengthen the financial position for the Phase 3 program.
The atopic dermatitis market is highly competitive, with established JAK inhibitors and biologics. Rezpegaldesleukin’s Treg mechanism offers a differentiated therapeutic approach that could capture a significant share of the market if the Phase 3 program succeeds.
In summary, the durable 36‑week maintenance data position Nektar for a pivotal Phase 3 trial and a potential valuation uplift, but the company must navigate financial challenges and a competitive landscape while executing its regulatory and capital‑raising strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.